Company Profiles

driven by the PitchBook Platform

Angiochem

Description

Developer of drugs designed to treat brain diseases and brain-related disorders. The company's drugs are use for the treatment of brain cancer, cancer metastases and neurodegenerative and metabolic diseases, enabling patients to start their treatment more quickly and result in a higher likelihood of a successful treatment.

2003

Founded

PRIVATE

Status

11-50

Employees

Series B

Latest Deal Type

$14M

Latest Deal Amount

$35.8M

Total Amount Raised

Description

Developer of drugs designed to treat brain diseases and brain-related disorders. The company's drugs are use for the treatment of brain cancer, cancer metastases and neurodegenerative and metabolic diseases, enabling patients to start their treatment more quickly and result in a higher likelihood of a successful treatment.

Website:

www.angiochem.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Pharmaceuticals
Biotechnology

Primary Office

201 President-Kennedy Avenue Suite PK-2880 Montreal, Quebec H2X 3Y7Canada +1 (514) 788-7800
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Angiochem's full profile, request a free trial.

Angiochem Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Angiochem Investors (4)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
BDC Healthcare Venture FundVenture CapitalMinority000 0000000 0000
Individual InvestorAngel (individual)Minority000 0000000 0000
ValeoCorporationMinority000 0000000 0000
VIMAC VenturesVenture CapitalMinority000 0000000 0000
BDC Healthcare Venture Fund Venture Capital
Individual Investor Angel (individual)
Valeo Corporation
VIMAC Ventures Venture Capital

Angiochem Executive Team (7)

NameTitleBoard
Seat
Contact
Info
Jean-Paul Castaigne MDPresident, Chief Executive Officer & Board Member
Jean Lachowicz Ph.DChief Scientific Officer
Catherine GagnonDirector, Corporate Development
Michel Demeule Ph.DDirector, Research
Richard BeliveauScientific Founder
Jean-Paul Castaigne MD President, Chief Executive Officer & Board Member
Jean Lachowicz Ph.D Chief Scientific Officer
Catherine Gagnon Director, Corporate Development
Michel Demeule Ph.D Director, Research
Richard Beliveau Scientific Founder

Angiochem Board Members (5)

NameRepresentingRoleSinceContact
Info
Jean-François PariseauBDC Healthcare Venture FundPartner000 0000
John HussAngiochemBoard Member000 0000
Martin Godbout Ph.DSelfBoard Member000 0000
Robert BlainSelfBoard Member000 0000
Sena Biswas Ph.DVIMAC VenturesManaging Director, Life Sciences000 0000
Jean-François Pariseau Partner BDC Healthcare Venture Fund
John Huss Board Member Angiochem
Martin Godbout Ph.D Board Member Self
Robert Blain Board Member Self
Sena Biswas Ph.D Managing Director, Life Sciences VIMAC Ventures
Request full access to PitchBook